New & Featured
-
Tetravalent Dengue Vaccine is Coming Home: Update Long Term Data & Recommendation
Takeda69 minutes -
Update vaccine recommendation for Children by PIDST 2023
Takeda14 minutes -
What's next for dengue? PART2- Update on Data of New Dengue Vaccine and Update Recommendation
Takeda30 minutes -
Update vaccine recommendation for Children by PIDST 2023
Takeda14 minutes -
DENGUE SMALL BITE BIG TREAT: Update on Data of New Dengue Vaccine
Takeda -
DENGUE SMALL BITE BIG TREAT: Q&A
Takeda20 minutes -
Challenge in management and diagnosis of Dengue & interesting Dengue cases in adults
Takeda45 minutes -
Challenge in management and diagnosis of Dengue in children
Takeda24 minutes -
Interesting Dengue cases in children from real-life practice
Takeda19 minutes -
What's next for Dengue vaccines
Takeda28 minutes -
Highlight from ICID congress 2022
Takeda43 minutes -
Case presentations in severe dengue: contemporary approaches to clinical management
Medscape45 minutes -
The 5th Asia Dengue Summit 2022 Highlight
Takeda10 minutes
Rerun Webinars
-
The 5th Asia Dengue Summit 2022 Highlight
Takeda10 minutes -
Highlight from PIDST symposium
Takeda8 minutes
Case Sharing Series
-
Saddleback Fever in Dengue Infections
Takeda11 minutes -
Case sharing: Dengue in Covid-19 Era
Takeda12 minutes
Meet Dengue Experts
-
Expanded Dengue Syndrome
Takeda8 minutes -
Case presentations in severe dengue: contemporary approaches to clinical management
Medscape45 minutes
Popular
-
Highlight from ICID congress 2022
Takeda43 minutes
Articles
-
ไข้เลือดออกและอาการเหนื่อยล้าหลังการติดเชื้อ จาก prospective cohort study
Takeda2 minutes -
ความเหมือนและความแตกต่างระหว่างพายุไซโตไคน์ (cytokine storms) ในไข้เลือดออกเฉียบพลันและโควิด-19
Takeda2 minutes -
Expert Opinion on 36-months Data of New Tetravalent Dengue Vaccine
Takeda -
Impact of COVID-19 pandemic on dengue
Takeda -
Moving Forward on the New Page
Takeda -
Case study Dengue Menstruation
Takeda -
Behind Vaccine Development - The Clinical Trial Process
Takeda -
Dengue Prevention and Control: Today's Challenge & Future Solution
Takeda -
ผลการศึกษาประสิทธิผลและความปลอดภัยของวัคซีนป้องกันไข้เลือดออกเมื่อติดตามครบ 3 ปี
Takeda